At a press conference at ASCO 2014, Prof Sznol talks about the results from an expanded phase I study which show that concurrent treatment with immunotherapy drugs ipilimumab and nivolumab produces an unprecedented median survival of roughly three and a half years (40 months) for patients with advanced melanoma.

Read the article or watch the interview for more.